Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials

Pâmela C.L. Ferreira; Bruna Bellaver; Guilherme Povala; Guilherme Bauer‐Negrini; Cristiano Schaffer Aguzzoli; João Pedro Ferrari‐Souza; Douglas Teixeira Leffa; Carolina Soares; Firoza Z Lussier; Marina Scop Medeiros; Cynthia Felix; Emma Patrice Ruppert; Francieli Rohden; Wyllians Vendramini Borelli; Helmet T. Karim; Rebecca L. Koscik; Bradley T. Christian; Rachael Wilson; Chang Hyung Hong; Hyun Woong Roh; Riddhi Patira; Dana Tudorascu; Eduardo R. Zimmer; Tobey J. Betthauser; Thomas K. Karikari; Beth E. Snitz; Sterling C. Johnson; Sang Joon Son; Tharick A. Pascoal

doi:10.1212/wnl.0000000000214441

Abstract

Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.

Affiliated Institutions

Related Publications

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Sebastian Palmqvist , Shorena Janelidze , Yakeel T. Quiroz +19 more

Among 1402 participants from 3 selected cohorts, plasma P-tau217 discriminated AD from other neurodegenerative diseases, with significantly higher accuracy than established plas...

2020 JAMA 1310 citations

The Amyloid-β Pathway in Alzheimer’s Disease

Harald Hampel , John Hardy , Kaj Blennow +12 more

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer’s disease (AD) pathophysiology. While the detailed molecular mechanisms...

2021 Molecular Psychiatry 1463 citations

Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials

Christian J. Wiedermann , Stefan Dunzendorfer , L Gaioni +2 more

Abstract Introduction It has been hypothesized that hyperoncotic colloids might contribute to acute kidney injury (AKI). However, the validity of this hypothesis remains unclear...

2010 Critical Care 146 citations

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ <sub>42</sub> in humans

Anne M. Fagan , Mark A. Mintun , Robert H. Mach +10 more

Abstract Objectives Amyloid‐β 42 (Aβ 42 ) appears central to Alzheimer's disease (AD) pathogenesis and is a major component of amyloid plaques. Mean cerebrospinal fluid (CSF) Aβ...

2005 Annals of Neurology 1238 citations

Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis

Domenico Praticò , Kunihiro Uryu , Susan Leight +2 more

Oxidative stress is a key feature in the Alzheimer's disease (AD) brain and manifests as lipid peroxidation (LPO). Isoprostanes (iPs) are specific and sensitive markers of in vi...

2001 Journal of Neuroscience 774 citations

Publication Info

Year: 2025
Type: article
Volume: 106
Issue: 1
Pages: e214441-e214441
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Pâmela C.L. Ferreira, 
                                
                                    Bruna Bellaver, 
                                
                                    Guilherme Povala
                                
                                et al.
                            
                            (2025). 
                            Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials. 
                            Neurology
                            , 106
                            (1)
                            , e214441-e214441.
                            https://doi.org/10.1212/wnl.0000000000214441
                        

Identifiers

DOI: 10.1212/wnl.0000000000214441